Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man
Felix Hasler, Daniel Bourquin, Rudolf Brenneisen, Franz X. Vollenweider
Journal of Pharmaceutical and Biomedical Analysis August 26, 2002 DOI: 10.1016/s0731-7085(02)00278-9 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Clinical study Peer reviewed |
|---|---|
| Sample size | 8 |
| Population | Human volunteers |
| Intervention | psilocybin |
| Dose | 212 ± 25 µg/kg body weight |
| Duration | 24 h |
| Topics | Psilocybin |
| Keywords | Urine Metabolite Excretion Incubation High-performance liquid chromatography Oral administration Pi Detection limit |
| Citations | 100 |
| Key points | Psilocin is partially excreted as psilocin-O-glucuronide, and enzymatic hydrolysis extends the time of detectability in urine. |
Abstract
In a clinical study eight volunteers received psilocybin (PY) in psychoactive oral doses of 212+/-25 microg/kg body weight. To investigate the elimination kinetics of psilocin (PI), the first metabolite of PY, urine was collected for 24 h and PI concentrations were determined by high-performance liquid chromatography with column switching and electrochemical detection (HPLC-ECD). Sample workup included protection of the unstable PI with ascorbic acid, freeze-drying, and extraction with methanol. Peak PI concentrations up to 870 microg/l were measured in urine samples from the 2-4 h collection interval. The PI excretion rate in this period was 55.5+/-33.8 microg/h. The limit of quantitation (10 microg/L) was usually reached 24 h after drug administration. Within 24 h, 3.4+/-0.9% of the applied dose of PY was excreted as free PI. Addition of beta-glucuronidase to urine samples and incubation for 5 h at 40 degrees C led to twofold higher PI concentrations, although 18+/-7% of the amount of unconjugated PI was decomposed during incubation. We conclude that in humans PI is partially excreted as PI-O-glucuronide and that enzymatic hydrolysis extends the time of detectability for PI in urine samples.
Citations in the library
Cited by 55
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies Journal of Psychopharmacology September 20, 2010
- The hallucinogenic world of tryptamines: an updated review. Archives of Toxicology August 1, 2015
- Psilocybin – Summary of knowledge and new perspectives European Neuropsychopharmacology December 17, 2013
- Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers Neuropsychopharmacology September 28, 2011
and 50 more in the library
Cites 10
- Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport December 1, 1998
- Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG Neuropsychopharmacology June 1, 1999
- Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d -methamphetamine in healthy volunteers Psychopharmacology February 18, 1999
- Advances and Pathophysiological Models of Hallucinogenic Drug Actions in Humans: A Preamble to Schizophrenia Research Pharmacopsychiatry July 1, 1998
- Increasing Use of “Ecstasy“ (MDMA) and other Hallucinogens on a College Campus Journal of American College Health May 1, 1994
and 5 more in the library